Theralase Technologies Inc. V.TLT

Alternate Symbol(s): V.TLT.WT | TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > The best competition has to offer

<< Previous

Bullboard Posts

Next >>

Comment by skier59on Dec 23, 2020 8:13am

110 Views

Post# 32167717

RE:RE:RE:The best competition has to offer

Hi HempDoc, nice to have you back posting ;)

CancerSlayer wrote:

CancerSlayer wrote:

enriquesuave wrote:
72% CR and 59% durable CR response at 12 months or better. Combination of N-803 with BCG. Combination drugs offer uneven comparison but gives us an idea of the most competitive treatment modality. This is still many more treatments using standard BCG protocol plus N-803 so about 12-15 treatments or more and has more side effects. But still very good outcome. If we match or beat their numbers we will shine as the next gold standard. Imo. Much more patient friendly just can't afford any screw ups.

https://immunitybio.com/category/press-releases/

Those are impactful %s and agree...this is our biggest competitor. Just want to clarify the 59% reported was the "percentage probability" of maintaining a CR at 12 months. This percentage would actually equate to a 42% durable CR at 12 months. Still commendable, but makes for a more conquerable target. Also, I believe the total number of treatments could even exceed "20" over 18 months in certain patients per their trial protocol.

If we accomplish similar efficacy (a realistic possibility & could even exceed), we should still be in the driver seat when considering the ease/simplicity of our "two" treatments, safety profile & treatment cost.

There were 51 responders out of a total of 71 evaluable patients & a reported 59% probability those 51 responders would maintain a durable CR. This would be 0.59 X 51 = 30 patients. 30 of 71 total evaluable patients = 42% durable response at 12 months.